BioLife Solutions Q1 revenue $36.2M (+115% YoY); net loss $7.1M vs $1.1M

BIOLIFE SOLUTIONS INC

GAAP EPS -$0.17 vs -$0.03; adjusted EBITDA -$814K vs +$2.8M a year ago.
Organic revenue growth 45%; biopreservation media revenue up 53%.
Gross margin GAAP 29%, adjusted 33%; improved sequentially from Q4 2021.
FY22 revenue guidance reaffirmed $159.5-$171M (34-44% growth); expects positive adj. EBITDA.
Management & board to accept shares in lieu of cash compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.